Management of Type 1 Diabetes with CKD Stage 4 and Proteinuria

Optimize ARB Dosing

The American College of Cardiology recommends titrating losartan from 25 mg to 50 mg daily initially, then to 100 mg daily based on blood pressure response and tolerability, as the renoprotective effect is dose-dependent, with higher doses providing greater protection against CKD progression 1, 2
Monitor serum creatinine and potassium within 2-4 weeks after each dose increase, and continue losartan unless creatinine increases by more than 30% from baseline or uncontrolled hyperkalemia develops, as recommended by the Annals of Internal Medicine 3, 4

The National Kidney Foundation recommends adding a thiazide or loop diuretic to enhance blood pressure control and antiproteinuric efficacy, as in major ARB trials, 60-90% of patients required concomitant diuretics to achieve blood pressure targets 1, 5
For CKD stage 4, loop diuretics are more effective than thiazides, and consider furosemide or bumetanide for volume management and blood pressure control, as recommended by Kidney International 4

The American Heart Association recommends aiming for systolic blood pressure <120 mmHg using standardized office measurement, as this target has been validated for reducing cardiovascular events and slowing CKD progression 3, 4

The American Diabetes Association recommends intensive glucose control to reduce the risk and slow progression of diabetic nephropathy, with a target HbA1c <7% to minimize microvascular complications while avoiding hypoglycemia in advanced CKD 6, 7, 8

The European Renal Association recommends using potassium-wasting diuretics and/or potassium-binding agents to maintain normal potassium levels rather than stopping the ARB, allowing continuation of renoprotective therapy 4

The Academy of Nutrition and Dietetics recommends restricting dietary sodium to <2.0 g/day and implementing protein restriction to 0.8 g/kg/day, with further restriction to 0.6 g/kg/day in selected patients, to enhance ARB efficacy and reduce proteinuria 4, 6, 7, 8

The American College of Cardiology recommends initiating statin therapy for cardiovascular disease prevention, as diabetic individuals with CKD are in the highest cardiovascular risk group, and consider low-dose aspirin for cardiovascular disease prevention, balancing benefit against bleeding risk 9

The National Kidney Foundation recommends checking serum creatinine, eGFR, and potassium within 2-4 weeks of any medication change, then at least every 3 months, and monitoring 24-hour urine protein or spot urine albumin-to-creatinine ratio every 3-6 months to assess treatment response 3, 5, 7